IDEAYA Biosciences, Inc. Variable Lease, Cost
IDEAYA Biosciences, Inc. (IDYA) reported Variable Lease, Cost of $600.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-04
- IDEAYA Biosciences, Inc. variable lease, cost for the quarter ending 2026-06-30 was $600.00K, a 0.00% change year-over-year.
- IDEAYA Biosciences, Inc. variable lease, cost for the quarter ending 2026-03-31 was $500.00K, a 16.67% decline year-over-year.
- IDEAYA Biosciences, Inc. variable lease, cost for the quarter ending 2025-12-31 was $400.00K.
- IDEAYA Biosciences, Inc. variable lease, cost for the quarter ending 2025-09-30 was $500.00K, a 25.00% increase year-over-year.
- IDEAYA Biosciences, Inc. variable lease, cost for fiscal 2025 was $2.20M, a 100.00% increase from fiscal 2024.
- IDEAYA Biosciences, Inc. variable lease, cost for fiscal 2024 was $1.10M, a 21.43% decline from fiscal 2023.
- IDEAYA Biosciences, Inc. variable lease, cost for fiscal 2023 was $1.40M, a 40.00% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. variable lease, cost for fiscal 2022 was $1.00M, a 0.00% change from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $600.00K 10-Q · filed 2026-08-04 | $1.20M 10-Q · filed 2026-08-04 | $1.50M derived: sum of 3 quarters · filed 2026-08-04 | $2.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-05 | $900.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.40M derived: sum of 3 quarters · filed 2026-05-05 | $2.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $900.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.50M derived: sum of 3 quarters · filed 2026-08-04 | $2.20M 10-K · filed 2026-02-17 |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-04 | $1.10M derived: sum of 2 quarters · filed 2026-08-04 | $1.80M 10-Q · filed 2025-11-04 | $1.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $600.00K 10-Q · filed 2026-08-04 | $1.20M 10-Q · filed 2026-08-04 | $1.20M derived: sum of 3 quarters · filed 2026-08-04 | $1.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-05 | $600.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.00M derived: sum of 3 quarters · filed 2026-05-05 | $1.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $400.00K derived: sum of 2 quarters · filed 2026-02-17 | $800.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.10M 10-K · filed 2026-02-17 |
| 2024-09-30 | $400.00K 10-Q · filed 2025-11-04 | $800.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.10M 10-Q · filed 2025-11-04 | $1.60M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $400.00K 10-Q · filed 2025-08-05 | $800.00K 10-Q · filed 2025-08-05 | $1.20M derived: sum of 3 quarters · filed 2026-02-17 | $1.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $400.00K 10-Q · filed 2025-05-06 | $800.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.10M derived: sum of 3 quarters · filed 2026-02-17 | $1.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $700.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.10M derived: sum of 3 quarters · filed 2026-02-17 | $1.40M 10-K · filed 2026-02-17 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-04 | $700.00K derived: sum of 2 quarters · filed 2024-11-04 | $1.00M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-06 | $700.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $1.00M 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $1.00M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |